<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Inauen P</dc:creator>
  <dc:creator>Hunziker T</dc:creator>
  <dc:creator>Gerber H</dc:creator>
  <dc:creator>Bruckner-Tuderman L</dc:creator>
  <dc:creator>Braathen LR</dc:creator>
  <dc:date>1994</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">We report a 6-year-old boy suffering from acquired epidermolysis bullosa, who presented with extensive lesions of the mucous membranes and disseminated, herpetiform and 'cluster of jewels'-like vesicles and bullae arising on erythematous plaques. Direct immunofluorescence showed linear deposits of IgG and C3 at the epidermal basement membrane zone. Indirect immunofluorescence demonstrated circulating autoantibodies (titre 1:128-1:256) directed at the blister floor of human NaCl-split skin, and reacting specifically with collagen VII of the anchoring fibrils, as demonstrated by immunoblotting. The disease was controlled with a combination of dapsone and prednisone. This case demonstrates the importance of modern immunological techniques in classifying childhood autoimmune bullous diseases, as precise diagnosis is important in determining an appropriate therapeutic regimen.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/260421</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1365-2133.1994.tb08598.x</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/7857848</dc:relation>
  <dc:source>The British journal of dermatology. - 1994</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Autoantibodies</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Basement Membrane</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Child</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Dapsone</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Drug Therapy, Combination</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Epidermolysis Bullosa Acquisita</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Fluorescent Antibody Technique</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Immunoglobulin G</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Mouth Mucosa</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Mucous Membrane</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Prednisolone</dc:subject>
  <dc:title xmlns:ns14="xml" ns14:lang="en">Childhood epidermolysis bullosa acquisita.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
